Related Experiment Video
Updated: Nov 10, 2025
08:54
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
14.2K
A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer
1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois. dcatenac@bsd.uchicago.edu.
Abstract:
To evaluate feasibility and efficacy, checkpoint inhibitor atezolizumab was added to neoadjuvant chemoradiotherapy prior to surgery for esophagogastric adenocarcinoma. The approach was deemed feasible, and while it did not demonstrate better clinical outcome to propensity-matched patients, biomarker investigation demonstrated that high inflammation in the sample at baseline predicted therapeutic benefit.See related article by van den Ende et al., p. 3351.
